FL118 is a novel survivin inhibitor that inhibits cancer stem cell-like properties.FL118 is a novel camptothecin analog with anticancer activity that inhibits epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway, thereby inhibiting migration and invasion of human breast cancer cells.

FL118 (0-200 nM; 24, 48 and 72 h) suppresses cell proliferation in ES-2 and SK-O-V3 cells. FL118 hinders cell migration in both ES-2 and SK-O-V3 cells, influencing the expression of cytoglobin (CYGB). Furthermore, FL118 inhibits the PI3K/AKT/mTOR signaling pathway and alters the expression levels of vimentin and E-cadherin in ovarian cancer cells.[1]
FL118 (0-500 nM; 0-72 h) induces dephosphorylation and degradation of DDX5. Through its regulation of DDX5, FL118 influences the expression of survivin, McL-1, XIAP, cIAP2, c-Myc, and mKras.[2]
FL118 (0-1 μM; 24, 48 h) exhibits significant cytotoxicity against the three tumor cell lines (A549, MDA-MB-231, and RM-1 cells). FL118 enhances PARP cleavage and triggers apoptosis in A549 cells, primarily arresting them at the G2/M phase.[3]

FL118 (5 and 10 mg/kg; p.o.; once a week; 20 days; Fmale BALB/c nude mice) dose-dependency suppressed the growth of ES-2 tumors by upregulating the expression level of CYGB.[1]
FL118 (0-1.5 mg/kg; i.p.; once every other day; five times) effectively eliminates human colon and head-and-neck tumors that acquire irinotecan or topotecan resistance.[4]
FL118 (1.5 mg/kg; i.v.; once) exhibits favorable pharmacokinetics profiles.[4]